234 related articles for article (PubMed ID: 33677005)
1. The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarof.
Bissonnette R; Gold LS; Rubenstein DS; Tallman AM; Armstrong AW
J Am Acad Dermatol; 2021 Jul; 85(1):e35-e36. PubMed ID: 33677005
[No Abstract] [Full Text] [Related]
2. The Therapeutic Aryl Hydrocarbon Receptor-Modulating Agent Tapinarof Regulates SEMA3A Expression in Human Keratinocytes through NRF2.
Tsuji G; Yumine A; Yamamura K; Takemura M; Kido-Nakahara M; Ito T; Nakahara T
J Invest Dermatol; 2024 Mar; 144(3):710-713.e8. PubMed ID: 37838333
[No Abstract] [Full Text] [Related]
3. Tapinarof to treat psoriasis.
Rodríguez Baisi K; Tollefson M
Drugs Today (Barc); 2020 Aug; 56(8):515-530. PubMed ID: 33025947
[TBL] [Abstract][Full Text] [Related]
4. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.
Vu YH; Hashimoto-Hachiya A; Takemura M; Yumine A; Mitamura Y; Nakahara T; Furue M; Tsuji G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321923
[TBL] [Abstract][Full Text] [Related]
5. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
Bissonnette R; Stein Gold L; Rubenstein DS; Tallman AM; Armstrong A
J Am Acad Dermatol; 2021 Apr; 84(4):1059-1067. PubMed ID: 33157177
[TBL] [Abstract][Full Text] [Related]
6. The mode of action of tapinarof may not only depend on the activation of cutaneous aryl hydrocarbon receptor signaling but also on its antimicrobial activity.
Haarmann-Stemmann T; Sutter TR; Krutmann J; Esser C
J Am Acad Dermatol; 2021 Jul; 85(1):e33-e34. PubMed ID: 33677003
[No Abstract] [Full Text] [Related]
7. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
Smith SH; Jayawickreme C; Rickard DJ; Nicodeme E; Bui T; Simmons C; Coquery CM; Neil J; Pryor WM; Mayhew D; Rajpal DK; Creech K; Furst S; Lee J; Wu D; Rastinejad F; Willson TM; Viviani F; Morris DC; Moore JT; Cote-Sierra J
J Invest Dermatol; 2017 Oct; 137(10):2110-2119. PubMed ID: 28595996
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
Eichenfield LF; Silverberg JI; Hebert AA; Chovatiya R; Brown PM; McHale KA; Rubenstein DS; Tallman AM
J Drugs Dermatol; 2024 Feb; 23(2):23-28. PubMed ID: 38306128
[TBL] [Abstract][Full Text] [Related]
9. Tapinarof Cream 1%: First Approval.
Keam SJ
Drugs; 2022 Jul; 82(11):1221-1228. PubMed ID: 35939180
[TBL] [Abstract][Full Text] [Related]
10. Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway.
Konstantinou MP; Jendoubi F; Hegazy S; Bouznad A; Tauber M; Bulai-Livideanu C; Paul C
J Am Acad Dermatol; 2021 Jul; 85(1):e37-e38. PubMed ID: 33677000
[No Abstract] [Full Text] [Related]
11. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
[TBL] [Abstract][Full Text] [Related]
12. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
[TBL] [Abstract][Full Text] [Related]
13. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
Peppers J; Paller AS; Maeda-Chubachi T; Wu S; Robbins K; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Jan; 80(1):89-98.e3. PubMed ID: 30554600
[TBL] [Abstract][Full Text] [Related]
15. Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
Bissonnette R; Vasist LS; Bullman JN; Collingwood T; Chen G; Maeda-Chubachi T
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):524-531. PubMed ID: 29389078
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.
Furue M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751111
[TBL] [Abstract][Full Text] [Related]
17. Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications.
Stein Gold L; Rubenstein DS; Peist K; Jain P; Tallman AM
J Am Acad Dermatol; 2021 Sep; 85(3):e201-e202. PubMed ID: 34111499
[No Abstract] [Full Text] [Related]
18. Reply to: Tapinarof cream 1% once daily and benvitimod 1% twice daily are two distinct topical medications.
Assaf J; Sarkis J; Tomb R
J Am Acad Dermatol; 2021 Sep; 85(3):e203. PubMed ID: 34048851
[No Abstract] [Full Text] [Related]
19. Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy.
Bissonnette R; Gold LS; Rubenstein DS; Tallman AM; Armstrong AW
J Am Acad Dermatol; 2021 Jul; 85(1):e39-e40. PubMed ID: 33676999
[No Abstract] [Full Text] [Related]
20. Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.
Furue M; Hashimoto-Hachiya A; Tsuji G
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
